In a decision filed March 28, Hon. Steven C. Seeger granted The Lansing Journal’s motion to dismiss the lawsuit filed by Lan-Oak Park District ...

For 2025, Merck said it still expects sales of $64.1 billion to $65.6 billion, but it lowered its adjusted earnings per share ...

Merck lowered its full-year profit guidance and said tariffs would mean an extra $200 million in costs this year. The stock ...

On a per-share basis, the Rahway, New Jersey-based company said it had profit of $2.01. Earnings, adjusted for one-time gains and costs, came to $2.22 per share. The results exceeded Wall Street ...

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...

A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs (shareholders) alleged that they bought MRK stock at artificially inflated ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co. has entered a competitive race for a new type of heart drug, announcing Tuesday it will pay ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor. In return for the ex-China rights to the drug, dubbed HRS-5346, Merck has ...

Merck (MRK), known as MSD outside of the United States and Canada, announced that the European Commission, or EC, has approved CAPVAXIVE, or Pneumococcal 21-valent Conjugate Vaccine, for active ...

Merck KGaA has developed a vision of a SMARTfacturing ecosystem. [Merck KGaA/Darmstadt, Germany] Merck KGaA has developed a SMARTfacturing vision ecosystem, which is a structured, multi-layered ...